CIPLA Stock Overview
Engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for CIPLA from our risk checks.
Cipla Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,463.05 |
| 52 Week High | ₹1,702.05 |
| 52 Week Low | ₹1,317.25 |
| Beta | 0.38 |
| 1 Month Change | 0.079% |
| 3 Month Change | 1.66% |
| 1 Year Change | 4.74% |
| 3 Year Change | 43.92% |
| 5 Year Change | 144.66% |
| Change since IPO | 45,238.72% |
Recent News & Updates
With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case
Mar 25
These 4 Measures Indicate That Cipla (NSE:CIPLA) Is Using Debt Safely
Feb 17Recent updates
With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case
Mar 25These 4 Measures Indicate That Cipla (NSE:CIPLA) Is Using Debt Safely
Feb 17Why Investors Shouldn't Be Surprised By Cipla Limited's (NSE:CIPLA) Low P/E
Jan 13We Ran A Stock Scan For Earnings Growth And Cipla (NSE:CIPLA) Passed With Ease
Dec 07
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Nov 10 Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 01Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk
Sep 29Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00
Jun 06Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's
May 21Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
May 14With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case
May 03Shareholder Returns
| CIPLA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.4% | -0.7% | -0.5% |
| 1Y | 4.7% | 10.5% | -2.4% |
Return vs Industry: CIPLA underperformed the Indian Pharmaceuticals industry which returned 10.5% over the past year.
Return vs Market: CIPLA exceeded the Indian Market which returned -2.4% over the past year.
Price Volatility
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 5.0% |
Stable Share Price: CIPLA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CIPLA's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | 27,764 | Umang Vohra | www.cipla.com |
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.
Cipla Limited Fundamentals Summary
| CIPLA fundamental statistics | |
|---|---|
| Market cap | ₹1.18t |
| Earnings (TTM) | ₹49.90b |
| Revenue (TTM) | ₹267.20b |
23.7x
P/E Ratio4.4x
P/S RatioIs CIPLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CIPLA income statement (TTM) | |
|---|---|
| Revenue | ₹267.20b |
| Cost of Revenue | ₹90.14b |
| Gross Profit | ₹177.06b |
| Other Expenses | ₹127.16b |
| Earnings | ₹49.90b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | 61.78 |
| Gross Margin | 66.26% |
| Net Profit Margin | 18.67% |
| Debt/Equity Ratio | 1.6% |
How did CIPLA perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield25%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 12:08 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipla Limited is covered by 80 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |